RxDoctor Payments Data

Nicole Hernandez Cordero, MD

Endocrinology, Diabetes & Metabolism · Bayamon, PRNPI 1861947137

Payments from drug & device makers

$4,245in general payments, 2019–2025

Across 172 payments — averaging $24.68 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boehringer Ingelheim$947
  • Dexcom, Inc.$754
  • Novo Nordisk$447
  • Amgen$446
  • AstraZeneca$375
  • Sanofi-aventis U.S. LLC$318
  • plus $958 from 11 others

What the payments were for

  • Food & beverage$4,18098%
  • Education$652%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Boehringer Ingelheim24$947
Dexcom, Inc.44$754
Novo Nordisk23$447
Amgen(2 entities)8$446
AstraZeneca17$375
Sanofi-aventis U.S. LLC15$318
PBG Puerto Rico LLC13$270
Merck9$160
Medtronic4$121
Lilly USA, LLC1$119
Johnson & Johnson5$112
Eli Lilly Export S.A. Puerto Rico Branch3$78
AbbVie2$36
Novartis1$18
Bayer Puerto Rico Inc.1$16
Abbott1$15
Corcept Therapeutics1$14

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,245 in reported general payments places this provider in the 40th percentile of 143 endocrinology, diabetes & metabolism providers in Puerto Rico.

See all endocrinology, diabetes & metabolism providers in Puerto Rico

Medicare billing

Part B allowed, 2024
$7,637
Medicare patients
22
Services billed
68

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide314$310,479
JardianceEmpagliflozin300$238,124
Synjardy XrEmpagliflozin/Metformin Hcl235$162,464
TrulicityDulaglutide127$128,902
FarxigaDapagliflozin Propanediol128$92,661
Trijardy XrEmpaglifloz/Linaglip/Metformin90$59,881
MounjaroTirzepatide54$59,397
JanuviaSitagliptin Phosphate60$59,312
SynthroidLevothyroxine Sodium804$57,173
SynjardyEmpagliflozin/Metformin Hcl68$52,550
Janumet XrSitagliptin Phos/Metformin Hcl78$48,725
TradjentaLinagliptin65$41,563
Soliqua 100-33Insulin Glargine/Lixisenatide32$31,782
ProliaDenosumab17$30,057
GlyxambiEmpagliflozin/Linagliptin34$24,291

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance, Synjardy Xr, Trijardy Xr, Synjardy, Tradjenta$947$607,433835 claims
Novo NordiskOzempic, Rybelsus$447$328,116332 claims
Lilly USA, LLCTrulicity, Mounjaro, Humalog, Humulin 70-30, Humulin N$119$213,499352 claims
MerckJanuvia, Janumet Xr$160$108,037138 claims
AstraZenecaFarxiga$375$92,661128 claims
AbbVieSynthroid$36$57,173804 claims
Sanofi-aventis U.S. LLCSoliqua 100-33, Lantus$318$50,377244 claims
AmgenProlia$446$30,05717 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 40th percentile of 143 endocrinology, diabetes & metabolism providers in Puerto Rico.

Other endocrinology, diabetes & metabolism in Bayamon

See the full list for Puerto Rico

Where these figures come from

Is this you, or does something look wrong? →